Negative reviews cluster around two complaints
European Respiratory Review
29 In the present study, FI assessment was done following the standard procedures described and standardized in a study by Searle et al
Semaglutide GLP-1 injections for weight loss are not recommended for use on patients who also have been diagnosed with type 1 diabetes, decreased kidney function or kidney disease, medullary thyroid cancer, or disease of the gallbladder
Stability and purity thanks to a separate powder chamber
Electrolysed reduced water (ERW), rich in H 2 , generated at the cathode during water electrolysis, has a high pH, low dissolved oxygen and an extremely negative redox potential (ORP).9 Moreover, in our recent study, we have demonstrated that human histiocytic lymphoma cells line U937 cultured in an ERWmedium could alleviate H 2 O 2 induced cytotoxicity of cells through the modulation of cellular redox state.10 Gastroesophageal reflux disease (GERD) is a clinical condition in which the reflux of gastric contents into the oesophagus induces complications and complex symptoms, impairing quality of life.11, 12 Even if the gastric mucosal acts as a protective barrier, pathogens and ingested materials can induce an unbalance of the redox cell state and GI inflammatory responses.13 In fact, several studies have highlighted that oxidative stress is involved in the development and progression of several GI disorders such as GERD, enteritis, gastritis, peptic ulcer, GI cancers and colitis.14, 15 ROS are produced within the GI tract, but their involvement in pathophysiology of GERD have not been well investigated.13, 16 The production of ROS in cell systems is attributable to the activity of many enzymes such as peroxidases, xanthine oxidase, NADPH oxidase, NADPH oxidase isoforms, glucose oxidase, lipoxygenases, myeloperoxidase and cyclooxygenases.13, 17 Proton pump inhibitors (PPIs) have been universally accepted as a firstline therapy for management of GERD and are among the most commonly prescribed medicines for gastroesophageal reflux and peptic ulcer disease.18 PPIs block acid production irreversibly inhibiting H + /K + adenosine triphosphatase in gastric parietal cell.19 Omeprazole, the first drug in this class, was introduced in 1989 and was followed by lansoprazole (1995), pantoprazole (2000), esomeprazole (2001) and dexlansoprazole (2009)
